Showing results (311-320 of 380) with videos related to

Sort By:
Pageof 38
Cancers|September 9, 2022
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsAnne Zaremba, Philipp Jansen, Rajmohan Murali, et al.
Cancers|February 15, 2022
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or ToxicityElias A T Koch, Anne Petzold, Anja Wessely, et al.
The New England Journal of Medicine|September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
International Journal of Cancer|June 23, 2022
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsAnne Zaremba, Philipp Jansen, Rajmohan Murali, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaLisa Zimmer, Susmitha Apuri, Zeynep Eroglu, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2021
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapyAdriana Hepner, Victoria G Atkinson, James Larkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsLisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
The Lancet. Oncology|October 12, 2012
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V Long, Uwe Trefzer, Michael A Davies, et al.
The New England Journal of Medicine|October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal MelanomaJessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
Journal for Immunotherapy of Cancer|June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanomaJames William Smithy, Allison Betof, Sebastian Klobuch, et al.
Pageof 38